title: Clinical outcome of dogs with grade-II mast cell tumors treated with surgery alone: 55 cases (1996-1999).
abstract: OBJECTIVE
  To determine outcome for dogs with grade-II mast cell tumors treated with surgery alone.
  
  
  METHODS
  Retrospective study.
  
  
  METHODS
  55 dogs.
  
  
  METHODS
  Medical records were examined, and signalment; location and size of tumor; staging status; dates of local recurrence, metastasis, death, or last follow-up examination; status of surgical margins; previous surgery; postoperative complications; and cause of death were recorded. Follow-up information was obtained via reexamination or telephone conversations with owners or referring veterinarians. Univariate analysis was performed to identify prognostic factors.
  
  
  RESULTS
  60 tumors in 55 dogs were included. Median follow-up time was 540 days. Three (5%) mast cell tumors recurred locally; median time to local recurrence was 62 days. Six (11%) dogs developed another mast cell tumor at a different cutaneous location; median time to a different location was 240 days. Three (5%) dogs developed metastases; median time to metastasis was 158 days. Fourteen dogs died; 3 deaths were related to mast cell tumor, and 7 were unrelated. The relationship with mast cell tumor was not known for 4. Median survival times were 151, 841, and 827 days, respectively, for these 3 groups. Forty-six (84%) dogs were free of mast cell tumors during the study period. A reliable prognostic factor could not be identified.
  
  
  CONCLUSIONS
  Results suggest that additional local treatment may not be required after complete excision of grade-II mast cell tumors and that most dogs do not require systemic treatment.
authors.affiliation: Comparative Oncology Unit, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins 80523, USA.
authors.forename: B
authors.initials: B
authors.lastname: Séguin
authors.forename: N F
authors.initials: NF
authors.lastname: Leibman
authors.forename: V S
authors.initials: VS
authors.lastname: Bregazzi
authors.forename: G K
authors.initials: GK
authors.lastname: Ogilvie
authors.forename: B E
authors.initials: BE
authors.lastname: Powers
authors.forename: W S
authors.initials: WS
authors.lastname: Dernell
authors.forename: M J
authors.initials: MJ
authors.lastname: Fettman
authors.forename: S J
authors.initials: SJ
authors.lastname: Withrow
mesh_terms: D000818:Animals; D004283:Dog Diseases / Q000601:surgery*; D004285:Dogs; D005260:Female; D005500:Follow-Up Studies; D008297:Male; D012515:Mast-Cell Sarcoma / Q000601:surgery / Q000662:veterinary*; D009364:Neoplasm Recurrence, Local / Q000662:veterinary; D012189:Retrospective Studies; D012878:Skin Neoplasms / Q000601:surgery / Q000662:veterinary*; D016019:Survival Analysis; D016896:Treatment Outcome